Retinal vein occlusions (RVOs) are a frequent cause of retinal vascular disease in patients older than 50 years. They can result in vascular congestion, damage to vessel endothelium, and the release of inflammatory cytokines-triggering macular edema and decreased vision.
Primary therapies for patients with RVO include intraocular injections of anti-vascular endothelial growth factor (VEGF) drugs and steroids.
However, use of intravitreal steroids has been limited due to risks of cataract formation and IOP elevations. These potential adverse effects have led investigators to look for alternative approaches for delivering drugs to the retina, said Glenn Yiu, MD.
The suprachoroidal space is an exciting, new route for ocular drug delivery, said Dr. Yiu, assistant professor of ophthalmology, University of California, Davis School of Medicine, Sacramento, CA.
Glenn Yiu, MD, PhD
E: [email protected]
This article was reviewed by Dr. Yiu. Dr. Yiu has no financial interest in any aspect of this report.